AM

Adel Moussa

IP Idenix Pharmaceuticals: 4 patents #3 of 30Top 10%
AP Atea Pharmaceuticals: 3 patents #1 of 2Top 50%
CN CNRS: 2 patents #31 of 1,153Top 3%
UM Universite De Montpellier: 2 patents #5 of 88Top 6%
Merck: 1 patents #377 of 961Top 40%
📍 Calgary, CA: #10 of 776 inventorsTop 2%
Overall (2019): #20,043 of 560,194Top 4%
7
Patents 2019

Issued Patents 2019

Showing 1–7 of 7 patents

Patent #TitleCo-InventorsDate
10519186 Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus Jean-Pierre Sommadossi 2019-12-31
10513534 2′-chloro nucleoside analogs for HCV infection Gilles Gosselin, Christophe Claude Parsy, Francois-Rene Alexandre, Houcine Rahali, Jean-Francois Griffon +5 more 2019-12-24
10251903 Process for making nucleoside phosphoramidate compounds Bryon Simmons, Kevin R. Campos, Artis Klapars, Alistair James Stewart, Benjamin Alexander Mayes +6 more 2019-04-09
10239911 Beta-D-2′-deoxy-2′-alpha-fluoro-2′-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment Jean-Pierre Sommadossi 2019-03-26
10238680 D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease Benjamin Alexander Mayes, Cyril B. Dousson, Gilles Gosselin, Claire Pierra, David Dukhan 2019-03-26
10231986 Amino acid phosphoramidate pronucleotides of 2′-cyano, azido and amino nucleosides for the treatment of HCV David Dukhan, Christophe Claude Parsy, Gilles Gosselin, Jean-Francois Griffon, Guillaume Brandt +3 more 2019-03-19
10202412 β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections Jean-Pierre Sommadossi 2019-02-12